Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a, Open-label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEN-221 in Patients With Somatostatin Receptor 2 Expressing Advanced Cancers, Including Gastroenteropancreatic or Lung or Thymus or Other Neuroendocrine Tumors or Small Cell Lung Cancer or Large Cell Neuroendocrine Carcinoma of the Lung

Next Previous
Trial Profile

A Phase 1/2a, Open-label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEN-221 in Patients With Somatostatin Receptor 2 Expressing Advanced Cancers, Including Gastroenteropancreatic or Lung or Thymus or Other Neuroendocrine Tumors or Small Cell Lung Cancer or Large Cell Neuroendocrine Carcinoma of the Lung

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nendratareotide uzatansine (Primary)
  • Indications Gastrointestinal cancer; Lung cancer; Malignant thymoma; Merkel cell carcinoma; Neuroendocrine carcinoma; Neuroendocrine tumours; Pancreatic cancer; Paraganglioma; Phaeochromocytoma; Small cell lung cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Tarveda Therapeutics

Most Recent Events

  • 16 Nov 2021 Primary endpoints have been added (MTD, RP2D, DLTs, DOR, CBR, OR). Number of treatment arms have been increased from 1 to 4.
  • 01 Nov 2021 According to a Tarveda Therapeutics media release, data will be presented at the North American Neuroendocrine Tumor Society (NANETS) 2021 Multidisciplinary NET Medical Virtual Symposium.
  • 08 Jun 2021 Results (data cut off: July 31, 2020; n=32) assessing the efficacy outcomes for patients enrolled in the GI mid-gut cohort and the safety data for the entire study presented at the 57th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top